Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
NEW YORK (Reuters Health) – For distinguishing epithelial ovarian cancer from a benign mass, an algorithm that uses HE4 and CA125 is more sensitive and objective than the…
Actinic Keratoses (AKs) are precancerous growths on the skin, typically characterized by rough and dry skin lesions. In this video, Gary Goldenberg, MD, Assistant Professor of Dermatology and…
Protein energy malnutrition can cause death in post-operative and cancer patients. New protein-rich snacks can help remedy that situation, and offer a new solution for cancer patients undergoing…
NEW YORK (Reuters Health) – Mounting evidence suggests that preoperative prostate specific antigen (PSA) kinetics are a poor marker of disease progression. During active surveillance for low-risk, low-volume…
NEW YORK (Reuters Health) – Up to 20% of tests for estrogen and progesterone receptors in breast cancers are false negatives or false positives, according to a consensus…
NEW YORK (Reuters Health) – Physicians should monitor serum testosterone levels during androgen-deprivation therapy (ADT) in men with prostate cancer, according to an April 16th online report in…
NEW YORK (Reuters Health) – Positron emission tomography (PET) of the liver is extremely unreliable in patients who’ve just had chemotherapy for colorectal cancer metastases, because the false-negative…
NEW YORK (Reuters Health) – Prostate specific antigen (PSA) doubling time as measured before radical prostatectomy does not predict biochemical progression after surgery, according to a report in…
NEW YORK (Reuters Health) – Accelerated radiation therapy is more effective than conventional fractionation for squamous cell carcinoma of the head and neck (HNSCC), but complications of treatment…
NEW YORK (Reuters Health) – Concomitant chemoradiation is better than sequential therapy for improving survival with locally advanced non-small-cell lung cancer (NSCLC), according to a patient-level meta-analysis reported…
